What amount sold does Hubble Bioscience, Inc. report in Form D filings?

The latest linked filings report $50K sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Hubble Bioscience, Inc.'s most recent SEC filing?

Hubble Bioscience, Inc.'s most recent Form D filing was on 2020-01-13.

How many investors does Hubble Bioscience, Inc. have?

The most recent Form D filing lists 2 investor(s).

What type of securities does Hubble Bioscience, Inc. offer?

Hubble Bioscience, Inc.'s SEC Form D filings indicate debt offerings.

Hubble Bioscience, Inc.

CIK: 0001799010·Biotechnology·PORTLAND, OR·Corporation·Founded 2019

Reported Sold

$50,000

Total Filings

Identified Offerings

Last Filed

Jan 13, 2020

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Jan 13, 2020Form D — New notice

Reported sold: $50,000 · Target: $500,000

Rule 506(b)·2 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 1 identified offering

$50,000

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

ANDREA M MCBETH

Related Person

Appears on 1 filing

PIPER J DOBNER

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Jan 13, 2020	New	$500,000	$50,000	2

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Opus KSD, Inc.

Biotechnology

Offering target: $680,801

Filed Oct 1, 2026